A randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of Nexvax2 in patients with celiac disease.

Trial Profile

A randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety and tolerability of Nexvax2 in patients with celiac disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs HLA DQ2 peptide vaccine (Primary)
  • Indications Coeliac disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors ImmusanT
  • Most Recent Events

    • 12 Oct 2017 According to an ImmusanT media release, data from this trial will be presented at the United European Gastrointestinal (UEG) Week, Nov 2017.
    • 12 May 2017 Results from this and other trial (see profile 215705) published in an ImmusanT Media Release
    • 11 May 2017 Status changed from active, no longer recruiting to completed, as reported in an article published in The Lancet Gastroenterology and Hepatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top